首页> 外文期刊>International journal of biomedical nanoscience and nanotechnology >Biosynthesis of monodispersed silver nanoparticles and their activity against Mycobacterium tuberculosis
【24h】

Biosynthesis of monodispersed silver nanoparticles and their activity against Mycobacterium tuberculosis

机译:单分散银纳米颗粒的生物合成及其对结核分枝杆菌的活性

获取原文
获取原文并翻译 | 示例
           

摘要

In this study, we report the characterisation of biosynthesised silver nanoparticles and investigate the antibacterial effects of biologically synthesised silver nanoparticles (AgNPs) on Mycobacterium tuberculosis. There is an urgent need to develop new anti-tuberculosis drugs, highlighted by the ongoing rise in tuberculosis (TB) cases worldwide. One worrying factor in the current TB problem is the prevalence of multi-drug resistant (MDR) strains. Increased resistance of Mycobacterium tuberculosis (M. tuberculosis) to antibiotics has led the researchers to develop a good antibacterial agent to overcome this problem. A colorimetric, microplate-based Alamar Blue assay (MABA) method was used to determine the MICs of isoniazid (INH), rifampin, streptomycin (SM), and ethambutol (EMB) for M. tuberculosis clinical isolates and silver nanoparticles against multi-drug resistance strains of M. tuberculosis isolated from MABA method.
机译:在这项研究中,我们报告了生物合成的银纳米颗粒的表征,并研究了生物合成的银纳米颗粒(AgNPs)对结核分枝杆菌的抗菌作用。迫切需要开发新的抗结核药,世界范围内结核病(TB)病例的不断增加突出了这一点。当前的结核病问题中令人担忧的一个因素是多药耐药(MDR)菌株的流行。结核分枝杆菌(M. tuberculosis)对抗生素的耐药性增强已导致研究人员开发出一种良好的抗菌剂来克服这一问题。基于比色板的Alamar Blue分析(MABA)方法用于测定异烟肼(INH),利福平,链霉素(SM)和乙胺丁醇(EMB)的结核分枝杆菌临床分离株和银纳米颗粒对多种药物的MIC MABA法分离的结核分枝杆菌耐药菌株。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号